NCT02523040View on ClinicalTrials.gov

Lenalidomide for Adult Histiocyte Disorders

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

12

Participants

Timeline

Start Date

August 31, 2015

Primary Completion Date

February 29, 2024

Study Completion Date

August 31, 2025

Conditions

Langerhans Cell Histiocytosis (LCH)Histiocytoses Erdheim-chester DiseaseHistiocytic Sarcoma (HS)

Interventions

DRUG

Lenalidomide

Trial Locations (1)

02115

Dana-Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Celgene

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER